The PORTOS assay could indicate when or when not to offer dose-escalated radiation for localized prostate cancer.

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

Providence Alaska Medical Center will be the first in the state to offer Pluvicto, an innovative therapy for metastatic ...

Nearly one in eight men will be diagnosed with prostate cancer and, as a new UCSF study finds, significantly more of these ...

A "Man Van" deployed in disadvantaged communities can help identify men at high risk for prostate cancer, according to a ...

Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective provincial registry of PSMA PET/CT for recurrent prostate cancer. While most ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ivan de Kouchkovsky discussing the impact of baseline PSMA PET in patients with metastatic ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

Paul Critchett was exposed to radiation while assigned to a U.S. Naval vessel that was servicing a nuclear submarine. He says ...